Rajinder Sidhu is the Associate Director for Research Governance and Operations for University College London Hospitals (UCLH) and University College London (UCL) Joint Research Office. She leads on the necessary governance, policies, and operations for both the sponsorship of studies at UCL and UCLH (ranging from clinical trials and advanced therapies through to observational and data programmes) and the systems and infrastructures required to host research at UCLH (commercial and non-commercial). Rajinder has over 17 years’ experience in senior operational and governance roles at UCLH/UCL and has led large change programmes to streamline systems and embed leaner ways of working across the organisation.
Prior to UCLH/UCL, Rajinder worked for Kings College London, Institute of Psychiatry as a researcher/coordinator for regional research studies into mental health services, and as a manager of international research centres. Rajinder also completed a PhD on consumerism within the NHS at Royal Holloway, University of London.
Marie Lefebvre is a Local Innovation Lead at Sanofi, specializing in developing and implementing innovative strategies to optimize clinical trials. With a Master’s degree in Physiology and Computer Sciences from Poitiers University, Marie brings extensive experience in digital project management and clinical operations to her role. At Sanofi, she leads the development and implementation of the UK Clinical Operation Innovation Road Map, focusing on gap analysis, change management, and the adoption of cutting-edge technologies. Beyond her professional achievements, Marie is passionate about sustainability, serving as a Climate Fresk facilitator and actively participating in various environmental initiatives within the industry.
Joe Sutton is a Biosample Project Leader at Roche based in the UK. He leads the operational activities relating to clinical biosampling including centralised screening, safety and biomarker analysis. In this role, Joe influences PhI/II clinical trial design across oncology, neurology and rare disease indications and ensures biosampling plans and biomarker strategies bring optimal value, insights and patient centricity. Prior to working with Roche, Joe worked as a consultant at A4PBio and as a Senior Pharmacology Scientist at GW Pharmaceuticals. Before joining the pharmaceutical industry, Joe completed academic research focusing on therapeutic resistance mechanisms of prostate cancer at University of Cambridge (CRUK Institute) and for completion of his PhD from Edinburgh Napier University.
Experienced scientist, specialised in inflammation and tissue repair, with a demonstrated history of delivering ambitious projects in the research industry. Skilled in various lab techniques, including cell culture and flow cytometry. Holder of a Doctorate of Philosophy (Ph.D.) focused on Cellular and Molecular Immunology from The Open University and the Vita-Salute San Raffaele University., followed by two post-docs at The University of Edinburgh. Currently highly focused on translating exciting scientific findings on the role of macrophages in tissue repair to the clinic at Resolution Therapeutics.
Peter Morley is leading the global effort to assess and reduce the environmental impact of Novo Nordisk clinical trials globally. He represents Novo Nordisk on the Sustainable Markets Initiative Health Systems Task Force (Digital Healthcare in Clinical Research), collaborating with industry and academia to accelerate the decarbonisation of the clinical trials sector through shared frameworks and tools.
With a background spanning more than 25 years in clinical operations, Peter combines his passion for sustainability with a sharp focus on innovation and digitalisation. This positions him at the forefront of setting the path for decarbonisation and driving the necessary changes to significantly lower the environmental impact of clinical trials.
